Stenoparib Dosing Regimen for Solid Tumor Resistance
Solution Overview
Problem
Current cancer treatment methods are inadequate, particularly for solid tumors like ovarian, breast, colon, pancreatic, and prostate cancers, as existing therapies often fail to provide significant therapeutic benefits due to resistance mechanisms and limited bioavailability of drugs like stenoparib and dovitinib.
Innovation Solution
A dosing regimen involving twice-daily administration of stenoparib or a combination of stenoparib and dovitinib, tailored to individual patient responses based on biomarker expression levels, to enhance drug exposure and overcome resistance, with dosing cycles ranging from 28 days ± 1 to 5 days and up to 100 cycles, and dosages adjusted to optimize therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If single daily dose of stenoparib is administered, then treatment simplicity is maintained, but therapeutic efficacy is insufficient due to short half-life and suboptimal drug exposure
Solution Approach 1:
The single daily dose is segmented into two separate administrations: a first dose in the morning and a second dose in the evening. This segmentation maintains treatment simplicity while ensuring sustained therapeutic drug levels throughout the day, overcoming the short half-life limitation of stenoparib and achieving optimal PARP inhibition.
2Reliability
If higher dosage of stenoparib is administered, then anti-tumor activity is enhanced, but risk of adverse effects and resistance development increases
Solution Approach 1:
The treatment employs periodic dosing with two administrations per day spaced approximately 12 hours apart, creating optimal periodic exposure to PARP inhibition. This periodic action maintains sustained therapeutic levels while avoiding continuous high-dose exposure that would increase adverse effects and resistance risk. The dosing cycle is repeated over multiple treatment cycles.
3Device complexity
If stenoparib is used alone, then treatment protocol is simple, but resistance mechanisms develop limiting therapeutic benefit
Solution Approach 1:
The patent combines stenoparib with dovitinib, a pan-tyrosine kinase inhibitor, to create a dual-mechanism treatment approach. Stenoparib inhibits PARP enzyme activity while dovitinib blocks receptor tyrosine kinases involved in tumor cell proliferation and survival. This merging of two different mechanisms of action overcomes resistance mechanisms that would limit single-agent therapy, while the established dosing schedules for both drugs keep protocol complexity manageable.
Data Source
AI summary
Described are methods of treating cancer (e.g., solid tumor cancer) using stenoparib monotherapy at BID dosing or a combination therapy including stenoparib (at BID dosing) and dovitinib (at QD dosing).